Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Daily Values

Growth Metrics

Others

Travere Therapeutics (TVTX) Notes Payables: 2011-2015

Travere Therapeutics' Notes Payables was N/A to $41.1 million in Q2 2015 from the same period last year, while for Jun 2015 it was $41.1 million, marking a year-over-year change of. This contributed to the annual value of $40.5 million for FY2014, which is N/A change from last year.
Latest data reveals that Travere Therapeutics reported Notes Payables of $41.1 million as of Q2 2015, which was up 1.58% from $40.5 million recorded in Q4 2014.
In the past 5 years, Travere Therapeutics' Notes Payables registered a high of $41.1 million during Q2 2015, and its lowest value of $25.0 million during Q1 2011.
Its 2-year average for Notes Payables is $40.8 million, with a median of $40.8 million in 2014.